[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Submit :: Contact Us ::
:: Volume 10, Issue 2 (Summer 2020) ::
J Fasa Univ Med Sci 2020, 10(2): 2261-2271 Back to browse issues page
Development of MF-59 adjuvant using chitosan derivatives to influenza vaccine
Alireza Loghmani 1, Nowruz Delirezh2 , Afagh Moattari3
1- Department of Microbiology, Faculty of Veterinary, Urmia University, Urmia, Iran , Alireza_trtr@yahoo.com
2- Department of Microbiology, Faculty of Veterinary, Urmia University, Urmia, Iran
3- Department of Virology, Faculty of Medicine, Shiraz University of Medical Sciences,Shiraz, Iran
Abstract:   (1070 Views)
Background & Objective: The influenza virus causes hundreds of deaths in the world. Despite the availability of some authorized vaccines for all age groups and its approved beneficial effects, the influenza is still a major problem for public health.
Materials & Methods: In this study, the adjuvant of MF59 was developed by methylglycol-chitosan. The physico-chemical characteristics and immune response stimulation of novel adjuvant were measured in combination with the influenza virus.
Results: The new adjuvant was produced with a nano-droplet diameter of 156 and Zeta potential of 29. The pH of adjuvant was not significantly changed for two years. Immunization of mice with developed adjuvant makes more HAI titer than MF59 adjuvant.
Conclusion: The favorable characteristics of physico-chemical properties and lack of local side effects of developed adjuvant as well as its strong humoral immunity can introduce it as a novel MF59 adjuvants.
 
 
Keywords: Vaccine, Influenza, MF59, Methylglycol-chitosan, Adjuvant
Full-Text [PDF 1189 kb]   (307 Downloads)    
Type of Study: Research | Subject: Immunology
Received: 2019/10/28 | Accepted: 2019/11/27 | Published: 2020/09/19
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA


XML   Persian Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Loghmani A, Delirezh N, Moattari A. Development of MF-59 adjuvant using chitosan derivatives to influenza vaccine. J Fasa Univ Med Sci. 2020; 10 (2) :2261-2271
URL: http://jabs.fums.ac.ir/article-1-2163-en.html


Volume 10, Issue 2 (Summer 2020) Back to browse issues page
Journal of Fasa University of Medical Sciences
Persian site map - English site map - Created in 0.04 seconds with 30 queries by YEKTAWEB 4319